Eptibind 0.75mg/ml Infusion
Marketer
Torrent Pharmaceuticals Ltd
Salt Composition
Eptifibatide (0.75mg/ml)
Overview Eptibind 0.75mg/ml Infusion
CardioThromb 0.75mg/ml infusion is an anticoagulant preventing the development of dangerous blood clots. It's employed in acute myocardial infarction treatment and to inhibit intra-cardiac clotting during angioplasty (a procedure enhancing coronary blood flow). CardioThromb 0.75mg/ml infusion is administered under strict medical supervision. Dosage and treatment length are determined individually by your physician. Concurrently prescribed medications should continue as directed, even post-infusion. Thrombocytopenia and heightened bleeding risk are potential side effects. Report any petechiae or hematuria/hematochezia promptly. Hypotension is another possible adverse reaction. Your doctor will thoroughly discuss the therapy's benefits and potential hazards before commencement. Pre-existing conditions such as bleeding disorders, hepatic or renal impairment, pregnancy, breastfeeding, or concurrent medications must be disclosed prior to administration.
Primary Ingredients of Eptibind 0.75mg/ml Infusion
No information provided. Please provide the text you wish me to rephrase.
Uses of Eptibind 0.75mg/ml Infusion
Thrombosis prophylaxis | Myocardial infarction prevention
Major Benefits of Eptibind 0.75mg/ml Infusion:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Eptibind 0.75mg/ml Infusion:
- Bleeding
- Decreased blood pressure
How to use Eptibind 0.75mg/ml Infusion:
This medication will be administered by your healthcare provider. Self-medication is not advised.
How Eptibind 0.75mg/ml Infusion works:
Thrombostop 0.75mg/ml infusion solution is an antithrombotic agent that inhibits platelet aggregation, thus reducing the risk of dangerous clot development.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Eptibind 0.75mg/ml Infusion may pose safety risks; seek medical advice before combining them.
PregnancySAFE IF PRESCRIBED
The intravenous formulation of Eptibind (0.75mg/ml) is typically deemed safe for pregnant individuals. Preclinical trials in animals revealed minimal or no harmful consequences to the fetus; however, clinical data from human studies are scarce.
Breast feedingCAUTION
Administering Eptibind 0.75mg/ml Infusion to breastfeeding mothers requires careful consideration. Lactation should cease until the mother's treatment concludes and the medication is fully cleared from her system.
DrivingNOT RELEVANT
Irrelevant; Eptibind 0.75mg/ml infusion is administered solely within a hospital setting.
KidneyCAUTION
Patients with kidney impairment should receive Eptibind 0.75mg/ml Infusion cautiously, potentially requiring dose modification. Consult a physician for guidance. Eptibind 0.75mg/ml Infusion is contraindicated in individuals with severe kidney disease.
LiverCONSULT YOUR DOCTOR
Data regarding Eptibind 0.75mg/ml Infusion use in patients exhibiting hepatic impairment is scarce. Physician consultation is advised. Eptibind 0.75mg/ml Infusion is contraindicated for individuals with advanced liver disease.
What if you forget to take Eptibind 0.75mg/ml Infusion :
Omit a dose of Eptibind 0.75mg/ml Infusion? Seek medical advice.
Facts to Know About Eptibind 0.75mg/ml Infusion
| Label | Value |
|---|---|
| Chemical Type | Amino acid and peptide analogs |
| Developing Habits | No. |
| Type of Therapy | KINSHIP |
| Action Class | GPIIb/IIIa receptor antagonists |
3,018 People bought this recently